Cargando…

Survival and Quality of Life Benefit after Endoscopic Management of Malignant Central Airway Obstruction

Background: Although interventional management of malignant central airway obstruction (mCAO) is well established, its impact on survival and quality of life (QoL) has not been extensively studied. Aim: We prospectively assessed survival, QoL and dyspnea (using validated EORTC questionnaire) in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Stratakos, Grigoris, Gerovasili, Vasiliki, Dimitropoulos, Charalampos, Giozos, Ioannis, Filippidis, Filippos T., Gennimata, Sofia, Zarogoulidis, Paul, Zissimopoulos, Athanasios, Pataka, Athanasia, Koufos, Nikos, Zakynthinos, Spyros, Syrigos, Konstantinos, Koulouris, Nikos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860795/
https://www.ncbi.nlm.nih.gov/pubmed/27162537
http://dx.doi.org/10.7150/jca.15097
Descripción
Sumario:Background: Although interventional management of malignant central airway obstruction (mCAO) is well established, its impact on survival and quality of life (QoL) has not been extensively studied. Aim: We prospectively assessed survival, QoL and dyspnea (using validated EORTC questionnaire) in patients with mCAO 1 day before interventional bronchoscopy, 1 week after and every following month, in comparison to patients who declined this approach. Material/Patients/Methods: 36 patients underwent extensive interventional bronchoscopic management as indicated, whereas 12 declined. All patients received full chemotherapy and radiotherapy as indicated. Patients of the 2 groups were matched for age, comorbidities, type of malignancy and level of obstruction. Follow up time was 8.0±8.7 (range 1-38) months. Results: Mean survival for intervention and control group was 10±9 and 4±3 months respectively (p=0.04). QoL improved significantly in intervention group patients up to the 6(th) month (p<0.05) not deteriorating for those surviving up to 12 months. Dyspnea decreased in patients of the intervention group 1 month post procedure remaining reduced for survivors over the 12th month. Patients of the control group had worse QoL and dyspnea in all time points. Conclusions: Interventional management of patients with mCAO, may achieve prolonged survival with sustained significant improvement of QoL and dyspnea.